Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Whitlock

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951Robert J Wells, Mary T Adams, Todd A Alonzo, et al.
Haematologica|March 2, 2016
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivationInge M van der Sluis, Lynda M Vrooman, Rob Pieters, et al.
Blood|October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemiaAlan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Paediatrics & Child Health|October 27, 2023
Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experienceGabriel Revon-Riviere, Leah C Young, Elizabeth A Stephenson, et al.
Cancer|April 29, 2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemiaTodd M Cooper, Todd A Alonzo, Robert B Gerbing, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Leukemia & Lymphoma|April 25, 2026
Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemiaMarie-Claude Pelland-Marcotte, Chantal Éthier, Alexis Manirakiza, et al.
Cancers|June 24, 2022
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical TrialArif Manji, Yvan Samson, Rebecca J Deyell, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951Robert J Wells, Mary T Adams, Todd A Alonzo, et al.
Haematologica|March 2, 2016
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivationInge M van der Sluis, Lynda M Vrooman, Rob Pieters, et al.
Blood|October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemiaAlan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Paediatrics & Child Health|October 27, 2023
Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experienceGabriel Revon-Riviere, Leah C Young, Elizabeth A Stephenson, et al.
Cancer|April 29, 2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemiaTodd M Cooper, Todd A Alonzo, Robert B Gerbing, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Leukemia & Lymphoma|April 25, 2026
Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemiaMarie-Claude Pelland-Marcotte, Chantal Éthier, Alexis Manirakiza, et al.
Cancers|June 24, 2022
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical TrialArif Manji, Yvan Samson, Rebecca J Deyell, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Pageof 8